evipedia.ai
← Back

Astragalus for Health & Longevity

Evidence Review created on 11/05/2026 using AI4L / Opus 5.5

Also known as: Astragalus membranaceus, Astragalus mongholicus, Astragalus propinquus, Astragali Radix, Radix Astragali, Huang Qi, Huangqi, Milk Vetch Root, Mongolian Milkvetch, Beg Kei

Motivation

Astragalus (Huang Qi) is the dried root of a flowering plant in the pea family that has served for more than two thousand years in traditional Chinese medicine as a daily tonic for energy and resistance to illness. It attracts people interested in healthy aging because its root contains compounds that act on immune cells and on an enzyme that maintains the protective caps at the ends of chromosomes.

The root is sold as dried slices for soups and teas, as granules and capsules, and as an expensive purified extract marketed for maintaining those chromosome caps. Human research has examined it mainly in kidney disease linked to diabetes, in blood sugar control and in fatigue, largely through small trials run in China and Taiwan, alongside laboratory and animal work on its individual compounds.

This review examines what human trials and supporting research show about astragalus as a supplement for health and longevity: which benefits have been studied and how strong that evidence is, which risks and drug interactions are known, how the root and its extracts are dosed and sourced, and which questions remain open.

Benefits - Risks - Protocol - Conclusion

This section lists expert commentary and long-form content that discusses astragalus and its extracts that activate telomerase (the enzyme that rebuilds the protective DNA caps on chromosomes) in depth.

Only four items are listed because no further content discussed astragalus in depth and was publicly accessible. Peter Attia’s only relevant content, a members-only Q&A episode on telomere-lengthening supplements (Attia AMA #76 show notes), is paywalled beyond a preview that does not mention astragalus. No relevant content on astragalus or TA-65 was found from Andrew Huberman: neither web searches nor the on-site search of his platform returned an episode or post discussing astragalus. Chris Kresser mentions astragalus only in passing, as a herb that stimulates one arm of the immune system and may worsen some cases of autoimmune thyroid disease (Kresser article on immune balancing for Hashimoto’s), which is too brief to qualify as an item.

Grokipedia

  • Astragalus mongholicus

    Covers the botany, taxonomy (listing Astragalus membranaceus as a synonym), cultivation and traditional uses of the medicinal root, plus its main compound classes and wild-population conservation status.

Examine

  • Astragalus

    Summarizes human evidence graded by outcome (allergic rhinitis [hay fever], stroke, immune health) and gives traditional dosing, including 30 g root with 6 g Angelica sinensis root and 5–10 mg astragaloside IV.

ConsumerLab

Systematic Reviews

This section lists systematic reviews and meta-analyses of astragalus in human studies, selected for size, citation and relevance to health and longevity.

No systematic review or meta-analysis focuses on the risks of astragalus; safety data come only from adverse-event reporting within efficacy reviews.

Mechanism of Action

Astragalus root acts through three compound groups rather than one target (summarized in a review, Liu 2017):

  • Polysaccharides: large sugar chains that are barely absorbed and act on immune cells of the gut wall, partly via toll-like receptor 4 (TLR4, a sensor for microbial patterns), activating macrophages (scavenger immune cells) and natural killer cells.
  • Saponins: astragaloside IV damps NF-κB (nuclear factor kappa B, a master switch for inflammatory genes) and oxidative stress in animal models. Its sugar-free core, cycloastragenol, activates telomerase (the enzyme that rebuilds telomeres, the protective DNA caps on chromosomes) in cultured cells and mice (Bernardes de Jesus 2011, co-authored by TA-65 developer Calvin Harley; most TA-65 research is seller-linked).
  • Isoflavones: formononetin and calycosin are weak plant estrogens with antioxidant activity.

Competing readings exist. Telomerase activation may sustain immune and stem-cell renewal, yet inherited long-telomere variants predispose to cancers (DeBoy 2023), making the same mechanism a theoretical cancer risk. Immune stimulation may aid infection resistance but prompts caution in autoimmune disease.

Pharmacology: selectivity is low (many targets). Astragaloside IV has 2.2% oral bioavailability (the share reaching the bloodstream) in rats (Gu 2004) and a 2.1–2.7-hour elimination half-life after intravenous infusion in volunteers (Xu 2013). Cycloastragenol is better absorbed (about 26% in rats) but extensively metabolized by liver hydroxylation (adding oxygen-hydrogen groups) and gut glucuronidation (attachment of a sugar acid for excretion) (Zhu 2010; Ma 2017). The specific liver enzymes and human tissue distribution are not mapped.

Historical Context & Evolution

  • Traditional origin: Huang qi (“yellow leader”) has been used for more than 2,000 years in Chinese medicine as a tonic for “qi” (vital energy), fatigue, sweating and slow-healing wounds, often in formulas such as Dang-gui buxue tang (astragalus with Angelica sinensis root) and in medicinal soups.
  • Cancer-care era: From the 1980s, researchers studied astragalus as an immune restorer during chemotherapy. A pooling of 34 trials of astragalus-based formulas with platinum drugs (chemotherapy built around platinum, which damages tumor DNA) found lower 12-month mortality and better tumor response (McCulloch 2006); critics argued that the analysis was affected by important bias (Firenzuoli 2006).
  • Injection era: Intravenous Huangqi injection spread in Chinese hospitals for heart failure and kidney disease, producing 62 small trials for heart failure alone that reviewers judged too low in quality to pool (Fu 2011).
  • Longevity era: Geron Corporation screened traditional herbs for telomerase activators and identified cycloastragenol. The licensed product TA-65 launched in 2007 inside a paid health program; a Geron-affiliated report on that program found fewer critically short telomeres but had no control group (Harley 2011). In 2018 the U.S. Federal Trade Commission (FTC) accepted a consent order settling charges that the seller’s age-reversal advertising claims were false or unsubstantiated (Federal Register notice).
  • Current standing: Oral root preparations have since gained randomized-trial support in diabetic kidney disease and diabetes, while the telomere approach still lacks independent outcome and cancer-safety data.

Expected Benefits

High 🟩 🟩 🟩

Lower Blood Glucose in Type 2 Diabetes ⚠️ Conflicted

Astragalus, added to the same diabetes therapy in both arms, lowered glucose markers in trials from multiple groups pooled by Hong (20 randomized controlled trials [RCTs, studies that assign treatment by chance], 953 participants; Hong 2024) and by Tian (13 studies; Tian 2016). HbA1c (glycated hemoglobin, a 3-month average of blood sugar) fell in both, in Tian’s only with oral decoctions (root simmered in water), but not in an eye-disease meta-analysis of root and formulas (Cheng 2013). Net reading: larger pools favor lowering, though most trials had high bias risk.

Magnitude: HbA1c 0.93 percentage points lower than control (95% confidence interval [CI, the range likely to contain the true effect] −1.22 to −0.64) and fasting glucose 0.67 mmol/L lower (95% CI −1.13 to −0.20) (Hong 2024).

Reduced Fatigue ⚠️ Conflicted

Two independent placebo-controlled trials of oral astragalus reduced fatigue: Liu’s Taiwanese post-stroke trial, scored on the Brief Fatigue Inventory (BFI, a validated fatigue scale) (Liu 2016), and Banihashemi’s Iranian trial in nurses with fatigue after COVID-19 (coronavirus disease 2019) (Banihashemi 2025). A meta-analysis of eight mostly injected-preparation cancer-fatigue trials agreed (Sheng 2025), but an intravenous polysaccharide (PG2) trial in breast cancer found no between-group difference (Shen 2024). Net reading: small oral trials and pooled injection trials favor benefit, while the one null trial leaves its size uncertain.

Magnitude: BFI score fell 9.8 points more than with placebo after 4 weeks (17.8 versus 8.0 points) (between-group p-value [probability of a difference this large arising by chance] = 0.01; no CI reported) (Liu 2016).

Medium 🟩 🟩

Slower Kidney Function Decline in Diabetic Kidney Disease ⚠️ Conflicted

Chan’s 48-week Hong Kong trial of oral granules added to standard care slowed decline in estimated glomerular filtration rate (eGFR, a blood-test measure of kidney filtering capacity) but found no effect on urine albumin (Chan 2024). Supporting reviews are indirect: the Cochrane review’s lower urine protein and serum creatinine came mostly from injection trials (Zhang 2014), and Wang’s remissions in membranous nephropathy (an autoimmune kidney-filter disease) came from astragalus formulas (Wang 2023). Net reading: one oral trial shows slower filtration loss, while effects on urine protein are inconsistent.

Magnitude: eGFR declined 4.6 mL/min/1.73 m² per year more slowly than with standard care alone (95% CI 1.5 to 7.6) over 48 weeks (Chan 2024).

Lower Blood Pressure

In Chan’s diabetic kidney disease trial, systolic blood pressure (the upper reading) was a secondary endpoint and ended lower with oral astragalus (Chan 2024). The Cochrane review pooled blood pressure from only 2 small trials (77 participants) with mixed comparators (Zhang 2014), so replication of the oral add-on effect rests on one group. All participants had kidney disease; effects in people with normal blood pressure are unknown.

Magnitude: Systolic blood pressure 7.9 mmHg lower than standard care at 48 weeks (95% CI −12.9 to −2.8) (Chan 2024).

Better Functional Recovery After Stroke

Chen’s double-blind trial gave 3 g astragalus three times daily for 14 days after acute hemorrhagic stroke and found greater gains on the Functional Independence Measure (FIM, a validated scale of daily-living independence) in 68 completers (Chen 2012). The same Taiwanese group ran the post-stroke fatigue trial (Liu 2016), so independent replication is lacking. A meta-analysis of 32 trials (2,527 patients) found the astragalus-based formula Buyang Huanwu decoction improved stroke-scale scores, indirect support from a multi-herb formula (Shao 2022).

Magnitude: FIM rose 10.8 points more than with placebo by week 12 (34.7 versus 23.9 points) (p < 0.05; no CI reported) (Chen 2012).

Reduced Knee Joint Pain

A single Indian placebo-controlled trial of a branded root extract (Axtragyl, 480 mg daily for 28 days) in 90 adults aged 18–60 with activity-related knee pain reported less pain on a visual analog scale (VAS, a 0–10 pain line) and better function on the WOMAC index (Western Ontario and McMaster Universities index, a validated knee pain-and-function questionnaire) (Lippi 2025). The trial was sponsored by Giellepi, the maker of Axtragyl. The effect size is unusually large for a 4-week supplement trial, and no other group has replicated it.

Magnitude: VAS 4.4 points lower than placebo at 28 days (1.2 versus 5.6, from 6.7 in both groups) (between-group p < 0.0001; no CI reported) (Lippi 2025).

Low 🟩

Better Heart Function in Chronic Heart Failure

Pooled Chinese trials found higher left ventricular ejection fraction (LVEF, the share of blood pumped per beat) and longer walking distance when Huangqi injection was added to standard drugs (Wang 2017). The evidence is indirect: it tested intravenous injection, not oral supplements.

Magnitude: LVEF 4.64 percentage points higher than standard treatment alone (95% CI 3.52 to 5.75) (Wang 2017).

Longer Survival Alongside Platinum Chemotherapy

In advanced non-small-cell lung cancer, a meta-analysis found astragalus-based formulas added to platinum chemotherapy lowered 12-month mortality (McCulloch 2006). Evidence is indirect: multi-herb formulas, not astragalus alone, and critics cite bias in the source trials.

Magnitude: Relative risk (RR, the ratio of event rates between groups) of death at 12 months 0.67 (95% CI 0.52 to 0.87) (McCulloch 2006).

Fewer Chemotherapy Side Effects

In colorectal cancer, a meta-analysis of 22 trials (1,409 patients) found astragalus-based formulas added to chemotherapy lowered blood-count drops, nausea, diarrhea and nerve toxicity (Lin 2019); a cervical cancer meta-analysis agreed (Shen 2021). Evidence is indirect: multi-herb formulas, not astragalus alone.

Magnitude: Neutropenia (low infection-fighting white cells) RR 0.52 (95% CI 0.44 to 0.62) and nausea and vomiting RR 0.56 (95% CI 0.46 to 0.68) versus chemotherapy alone (Lin 2019).

Less Radiation-Induced Lung Injury

A meta-analysis of 25 trials (1,762 patients) found that astragalus-containing formulas given with chest radiotherapy lowered the incidence of radiation-induced lung injury (lung inflammation and scarring after radiation) and eased breathing difficulty (Pang 2022). Evidence is indirect: multi-herb formulas, not astragalus alone.

Magnitude: Radiation-induced lung injury RR 0.49 versus radiotherapy alone (95% CI 0.37 to 0.65; 10 trials) (Pang 2022).

Relief of Seasonal Allergic Rhinitis

A 6-week placebo-controlled trial in 48 adults with hay fever found less runny nose but no difference in total symptom score (Matkovic 2010). Evidence is indirect: the product (Lectranal) combined astragalus with other herbs and minerals.

Magnitude: Direction only: rhinorrhea (runny nose) intensity decreased versus placebo in moderate-to-severe hay fever; the literature reports no outcome figure for it (Matkovic 2010).

Lower Blood Cholesterol ⚠️ Conflicted

A meta-analysis of 7 Chinese trials (542 participants) found Huangqi injection lowered total cholesterol versus control (Yu 2018), but pooled root and formula trials in diabetic retinopathy (diabetes-related damage to the retina) showed no reduction (Cheng 2013). Evidence is indirect: injection or multi-herb formulas. Net reading: no consistent cholesterol benefit.

Magnitude: Total cholesterol standardized mean difference (SMD, effect size in standard-deviation units) −1.13 versus control (95% CI −2.09 to −0.16) with injection (Yu 2018); mean difference −0.96 versus control (95% CI −2.19 to 0.27, not significant) with root and formulas (Cheng 2013).

Less Heart-Muscle Injury in Viral Myocarditis

A systematic review of 28 trials (2,522 participants) found lower blood markers of heart-muscle damage when astragalus was added to standard care for viral myocarditis (heart-muscle inflammation after a viral infection) (Zheng 2020). Evidence is indirect: nearly all trials used intravenous injection, not oral supplements.

Magnitude: Cardiac troponin I (a protein released by damaged heart muscle) SMD −1.71 versus standard care alone (95% CI −1.88 to −1.53; 8 trials, 770 participants) (Zheng 2020).

Fewer Flare-Ups in Stable Chronic Obstructive Pulmonary Disease

A systematic review of 25 trials (1,661 participants) found that oral Huangqi formulas added to conventional therapy improved lung function and reduced exacerbations (acute flare-ups) of chronic obstructive pulmonary disease (Wu 2013). Evidence is indirect: multi-herb formulas, not astragalus alone.

Magnitude: Exacerbation frequency 0.97 lower than with conventional therapy alone (mean difference, 95% CI −1.57 to −0.37; 4 trials) (Wu 2013).

Better Blood Counts in Aplastic Anemia

A meta-analysis of 10 trials (720 patients) found higher white-cell, hemoglobin and platelet counts when Huangqi injection was added to androgens (male-type hormones that stimulate blood formation) for aplastic anemia (bone-marrow failure) (Zhu 2015). Evidence is indirect: intravenous injection, not oral supplements.

Magnitude: Hemoglobin SMD 1.70 versus androgens alone (95% CI 0.63 to 2.76) (Zhu 2015).

Less Nerve Damage in Diabetic Peripheral Neuropathy

A meta-analysis of 48 Chinese trials (3,759 patients) found lower neuropathy symptom scores and faster nerve conduction when Huangqi-based formulas were given for diabetic peripheral neuropathy (nerve damage in the feet and hands from diabetes) (Jing 2024). Evidence is indirect: multi-herb formulas, not astragalus alone.

Magnitude: Toronto Clinical Scoring System (a validated neuropathy severity scale) score 1.50 points lower than conventional drugs alone (mean difference, 95% CI −1.83 to −1.17) (Jing 2024).

Better Vision in Diabetic Retinopathy

A meta-analysis of 16 trials (977 participants) found better visual acuity and retinal findings when radix astragali or astragalus-based formulas were given for diabetic retinopathy (Cheng 2013). Evidence is indirect: the pooled preparations included multi-herb formulas, and trial quality was low.

Magnitude: Visual acuity 0.20 higher than control on the trials’ acuity scale (mean difference, 95% CI 0.09 to 0.30) (Cheng 2013).

Fewer Respiratory Infections

A multicenter placebo-controlled trial in 351 children aged 2–6 found the astragalus-based formula Yupingfeng reduced recurrent respiratory infections (Xu 2022). Evidence is indirect: a three-herb formula in young children. A Cochrane review of oral astragalus alone found no placebo-controlled trial (Su 2016).

Magnitude: 34.3 percentage points more children on Yupingfeng than on placebo returned to a normal infection frequency over 52 weeks of follow-up (73.1% versus 38.8%; no CI reported) (Xu 2022).

Less Neck and Arm Pain in Cervical Radiculopathy

A meta-analysis of 8 trials (783 participants) found that Huangqi Guizhi Wuwu decoction, alone or added to conventional treatment, improved cervical radiculopathy (neck pain radiating into the arm from a compressed spinal nerve root) (Liang 2020). Evidence is indirect: a five-herb astragalus formula, and trial quality was low.

Magnitude: Neck Disability Index (a validated neck-function questionnaire) improved 9.2 points more than control (mean difference, 95% CI 8.28 to 10.11) (Liang 2020).

Better Lung Function in Idiopathic Pulmonary Fibrosis

A meta-analysis of 17 Chinese trials (1,211 patients) found that formulas built on astragalus and Angelica sinensis root, mostly given alongside prednisone, improved lung function and walking distance in idiopathic pulmonary fibrosis (progressive lung scarring of unknown cause) (Zhang 2020). Evidence is indirect: multi-herb formulas, and trial quality was low.

Magnitude: Forced vital capacity (FVC, the air volume exhaled after a full breath) 6.23 percentage points of predicted higher than control (mean difference, 95% CI 3.73 to 8.74; 5 trials, 459 participants) (Zhang 2020).

Fewer Relapses of Cough-Variant Asthma

A meta-analysis of 7 Chinese trials (512 patients) found that Huangqi Xixin decoction, used instead of conventional drugs, lowered relapse of cough-variant asthma (asthma presenting mainly as chronic cough) (Wang 2022). Evidence is indirect: a multi-herb formula, and trial quality was low.

Magnitude: Odds ratio (the ratio of the odds of the event between groups) of relapse 0.20 versus conventional Western medicine (95% CI 0.09 to 0.44; 2 trials, 130 patients) (Wang 2022).

Better Endoscopic Healing in Chronic Gastritis

A systematic review of 9 Chinese trials (979 participants) found that Huangqi Jianzhong decoction, added to conventional drugs, improved endoscopic findings in chronic gastritis (long-standing inflammation of the stomach lining) (Wei 2015). Evidence is indirect: a multi-herb formula, and trial quality was poor.

Magnitude: Odds ratio of overall endoscopic improvement 3.78 versus conventional drugs alone in chronic superficial (non-atrophic) gastritis (95% CI 1.29 to 11.06) (Wei 2015).

Faster Recovery in Acute Pancreatitis

A meta-analysis of 6 Chinese trials (619 patients) found that astragalus injection added to general treatment raised clinical response rates and shortened abdominal pain, distension and bowel-sound recovery in acute pancreatitis (sudden inflammation of the pancreas) (Cao 2025). Evidence is indirect: injection, not oral supplements, in unblinded trials.

Magnitude: Odds ratio of clinical response 3.13 versus general treatment alone (95% CI 1.93 to 5.08; 6 trials) (Cao 2025).

Better Liver Function in Cirrhosis

A meta-analysis of 11 Chinese trials (1,086 patients) found that Huangqi injection given with Danshen (Salvia miltiorrhiza) injection raised serum albumin and lowered bilirubin and blood markers of scarring in liver cirrhosis (advanced liver scarring) (Zhu 2013). Evidence is indirect: two injected herbs together, not oral astragalus, in low-quality trials.

Magnitude: ALT (alanine aminotransferase, a liver enzyme) 18.11 U/L lower than control (mean difference, 95% CI −28.42 to −7.81) (Zhu 2013).

Speculative 🟨

Telomere Lengthening

TA-65 lengthened white-blood-cell telomeres versus placebo at one of two doses (Salvador 2016, authors from seller TA Sciences). Telomere length is an unvalidated biomarker; no outcome benefit is shown.

Immune Modulation ⚠️ Conflicted

A meta-analysis found lower inflammatory proteins and higher T-cell markers (Zhang 2023). TA-65 lowered high-sensitivity C-reactive protein (hsCRP, an inflammation marker) (Bawamia 2023), but not when pooled (Su 2025). Net reading: inconsistent, unvalidated biomarker shifts.

Longer Healthspan and Lifespan ⚠️ Conflicted

TA-65 improved glucose tolerance, bone and skin in mice but did not extend lifespan (Bernardes de Jesus 2011). Pooled human trials showed no frailty benefit (Su 2025). Net reading: no healthspan benefit shown in people.

Protection of Cognition

Astragaloside IV protects neurons in animal models (a review, Liu 2017); two Chinese Alzheimer’s disease trials of oral astragalus have no published results (NCT06694597; NCT05578443). The basis is mechanistic only.

Benefit-Modifying Factors

  • Genetic polymorphisms: No study has tested whether any gene variant changes the benefits of astragalus; available pharmacogenetic data address drug transport, not benefit (Zhou 2013).
  • Baseline biomarkers: In diabetic kidney disease, a meta-analysis found the benefit of astragalus injection tracked baseline serum creatinine (Zhang 2019). TA-65 telomere gains were shown in older adults positive for cytomegalovirus (CMV, a common latent herpes virus that ages immune cells) (Salvador 2016).
  • Sex: No trial formally analyzed sex differences. Less chemotherapy fatigue appeared mainly in premenopausal women (Shen 2024), and diastolic (relaxation-phase) heart function improved in postmenopausal hypertensive women given 10 g daily (Li 2018).
  • Pre-existing conditions: Nearly all positive trials enrolled people with diabetes, kidney disease, stroke, heart failure or cancer; in healthy adults only telomere, immune and exercise-recovery markers have been tested.
  • Age: Telomere and lymphocyte (infection-fighting white cell) effects of TA-65 were reported in adults aged 53–87 and over 65 (Salvador 2016; Bawamia 2023), where immune aging is most advanced; younger adults were studied mainly for exercise recovery.

Potential Risks & Side Effects

High 🟥 🟥 🟥

No risk reaches High: no adverse effect has been shown in controlled trials from more than one independent research group, and controlled trials report adverse-event rates similar to or lower than comparison groups.

Medium 🟥 🟥

No risk reaches Medium: no single controlled trial or comparative observational study has shown a statistically significant excess of any adverse event with oral astragalus.

Low 🟥

Mild Gastrointestinal Upset ⚠️ Conflicted

Nausea and stomach discomfort occurred slightly more often with a root extract than placebo in one trial (Lippi 2025). Chan’s larger trial found fewer patients with adverse events than standard care (Chan 2024). Net reading: any digestive effect is mild and inconsistent.

Magnitude: 4 of 45 on astragalus versus 1 of 45 on placebo had mild gastrointestinal events that resolved within a day (Lippi 2025).

Loss of Immunosuppressant Drug Effect

A child with nephrotic syndrome (a kidney disorder with heavy urine protein loss) had tacrolimus (an anti-rejection drug) levels nearly halve after starting granules containing astragalus (Yang 2021). Evidence is one indirect case report: the granules were a multi-herb formula, and cyclophosphamide was added simultaneously.

Magnitude: Tacrolimus blood concentration fell by nearly half in one patient (single case report; no control group) (Yang 2021).

Rash and Transient Liver Test Changes

Healthy volunteers receiving intravenous astragalosides had mild rash and raised bilirubin that resolved spontaneously (Xu 2013). Evidence is indirect (injection) and uncontrolled.

Magnitude: Not quantified in available studies. The only report is an uncontrolled volunteer study that described these events without giving rates or a comparison group.

Cancer Promotion by Telomerase Activation

Inherited variants of POT1 (a telomere-capping gene) that keep telomeres long predispose carriers to clonal blood disorders (blood-cell lines expanding from a single mutated cell) and to lymphomas and other cancers (DeBoy 2023). Evidence is indirect: inherited long telomeres, not TA-65 or cycloastragenol, whose cancer risk is untested.

Magnitude: Clonal hematopoiesis in 8 of 12 POT1 carriers versus 2 of 21 noncarrier relatives (odds ratio [the ratio of the odds of the event between groups] 10.1, 95% CI 2.6 to 84.2) (DeBoy 2023).

Speculative 🟨

Worsening of Autoimmune Disease ⚠️ Conflicted

The National Center for Complementary and Integrative Health warns it might worsen symptoms (NCCIH fact sheet). Pooled trials found multi-herb astragalus formulas with immunosuppressants lowered lupus kidney-disease activity (Li 2024). Net reading: worsening remains unshown.

Harm to the Fetus

Animal studies suggest astragalus can be toxic to the fetus during pregnancy (NCCIH fact sheet). No human data exist; the basis is animal work only.

Poisoning from Misidentified Species

Some wild Astragalus species (locoweeds) contain swainsonine, which causes lasting nerve damage in livestock (a review, Stegelmeier 1999). No human cases from supplements are reported; the basis is livestock data only.

Risk-Modifying Factors

  • Genetic polymorphisms: Carriers of telomere-lengthening POT1 variants have more clonal blood disorders and cancers (DeBoy 2023), the greatest theoretical risk for telomerase activators. In ABCB1 3435CC carriers (ABCB1 encodes the P-glycoprotein drug pump), root extract slowed fexofenadine elimination (Zhou 2013).
  • Baseline biomarkers: Low-normal blood pressure or tightly controlled glucose raise the chance of additive lowering, given the 7.9 mmHg systolic reduction (Chan 2024) and the HbA1c reduction in a meta-analysis (Hong 2024) seen with add-on use.
  • Sex: Pregnancy is the main sex-specific concern, given animal fetal toxicity (NCCIH fact sheet). The isoflavones are weak plant estrogens; no human data show harm in hormone-sensitive conditions.
  • Pre-existing conditions: Autoimmune disease and organ transplantation on immunosuppressants increase risk (NCCIH fact sheet; Yang 2021). A personal cancer history is a theoretical concern for telomerase activators, inferred from inherited long telomeres (DeBoy 2023).
  • Age: Trials up to age 87 showed no age-specific adverse signal (Salvador 2016), but older adults more often take blood pressure, diabetes and immunosuppressant drugs that raise interaction risk.

Key Interactions & Contraindications

Documented interactions:

  • Tacrolimus (and other calcineurin inhibitors, anti-rejection drugs such as cyclosporine): tacrolimus levels nearly halved after astragalus-containing granules were added (Yang 2021). Consequence: loss of immunosuppression, risking rejection or relapse. Avoid; if combined, drug-level monitoring.
  • Glucose-lowering drugs (metformin, sulfonylureas [drugs that push the pancreas to release insulin] such as gliclazide, insulin): a meta-analysis of add-on trials shows further glucose lowering (Hong 2024). Consequence: additive lowering, with low-glucose risk under sulfonylureas or insulin. Mitigation: glucose checks during the first weeks.
  • Blood pressure drugs (ACE inhibitors [drugs blocking a vessel-tightening hormone] such as enalapril; angiotensin receptor blockers [drugs blocking that hormone’s receptor] such as losartan): added to standard care, systolic pressure ended 7.9 mmHg lower (Chan 2024). Consequence: additive lowering, dizziness. Mitigation: home readings.
  • Platinum chemotherapy (cisplatin, carboplatin): no harmful interaction found; pooled trials of astragalus-based formulas reported lower 12-month mortality and higher tumor response rather than reduced chemotherapy effect (McCulloch 2006). Mitigation: coordination with the oncology team.
  • Docetaxel (a taxane, a chemotherapy class that blocks cell division): no pharmacokinetic interaction found; the oral astragalus-based multi-herb formula Jinfukang did not alter docetaxel blood levels in 21 patients with advanced lung cancer (Cassileth 2009). Consequence: none detected. Mitigation: coordination with the oncology team.
  • Fexofenadine (a P-glycoprotein [gut-cell drug pump] substrate): exposure unchanged versus placebo after 7 days of root extract granules in 14 volunteers, but elimination slowed in ABCB1 3435CC carriers (Zhou 2013). Consequence: possibly higher substrate levels in carriers; digoxin, dabigatran untested. Mitigation: digoxin level checks.

Theoretical interactions (inferred from mechanism, not studied in humans):

  • Drugs cleared by the liver enzyme CYP2D6 (metoprolol, codeine; over-the-counter dextromethorphan): astragaloside IV inhibited CYP2D6 in liver microsomes (liver-cell fragments) and doubled metoprolol exposure in rats (Shi 2022). Consequence: higher drug levels, slow heart rate. Mitigation: pulse monitoring.
  • Drugs cleared by the liver enzyme CYP3A4 (atorvastatin, over-the-counter omeprazole): in rats, astragaloside IV lowered omeprazole exposure (Liu 2019), but whole root raised midazolam exposure by inhibiting CYP3A4 (Pao 2012). Consequence: weaker or stronger drug effect. Mitigation: drug-effect or level checks after starting.
  • Immunosuppressive drugs (mycophenolate, azathioprine, prednisone, cyclophosphamide, methotrexate): inferred from the immune-stimulating action of astragalus opposing these drugs; the NCCIH flags a possible interaction without human data (NCCIH fact sheet). Consequence: weaker immunosuppression. Mitigation: disease-activity tracking.
  • Lithium: inferred from the traditional diuretic (urine-increasing) action of astragalus, which may alter lithium clearance. Consequence: unstable lithium levels. Mitigation: lithium-level checks after starting or stopping.
  • Immune-stimulating supplements (echinacea, beta-glucans, medicinal mushrooms): additive immune activation inferred from shared mechanism. Consequence: compounded stimulation, relevant mainly in autoimmune disease.
  • Glucose- or blood-pressure-lowering supplements (berberine, cinnamon, garlic, hibiscus): additive lowering inferred from astragalus’s own glucose and blood pressure effects. Consequence: low glucose or dizziness. Mitigation: home glucose and blood pressure checks.
  • Vaccination: astragalus polysaccharides boost vaccine immune responses in animal studies, so effects on vaccine responses in people are possible but unmeasured. Consequence: unknown direction. Mitigation: none established.

Populations who should avoid Astragalus:

  • People with autoimmune diseases (e.g., lupus, rheumatoid arthritis, multiple sclerosis), per the federal advisory (NCCIH fact sheet).
  • Organ transplant recipients taking calcineurin inhibitors (tacrolimus, cyclosporine) or other immunosuppressants (NCCIH fact sheet; Yang 2021).
  • Pregnant or breastfeeding women: inferred from fetal toxicity in animal studies (NCCIH fact sheet); no human data exist, and none at all for breastfeeding.
  • For telomerase activators (TA-65, cycloastragenol): people with active cancer, a cancer history, or known telomere-lengthening germline variants such as POT1 mutations; this is inferred from the cancer predisposition of inherited long telomeres (DeBoy 2023); no human data on the supplements.

Risk Mitigation Strategies

Doses and timings below follow common practice unless cited.

  • Medication review before starting: prevents loss of immunosuppression and additive drug effects by screening for tacrolimus, cyclosporine, immunosuppressants, diabetes and blood pressure drugs (Yang 2021).
  • Glucose checks in the first 2–4 weeks: on insulin or sulfonylureas, fasting glucose or continuous glucose monitor readings detect additive glucose lowering early and prevent hypoglycemia (low blood sugar).
  • Home blood pressure log: readings twice weekly for the first month detect additive lowering on blood pressure–lowering drugs; dizziness or a fall in readings prompts dose review with the prescriber.
  • Low starting dose with food: beginning at about half the target dose (e.g., 250 mg extract or 5 g root) for 1 week limits the mild nausea seen in trials (Lippi 2025).
  • Verified species and contaminant testing: buying root labeled Astragalus mongholicus or Astragalus membranaceus with third-party testing prevents exposure to swainsonine-containing locoweeds (a review, Stegelmeier 1999) and heavy-metal contamination.
  • Cancer screening before telomerase activators: up-to-date age-appropriate screening and excluding known long-telomere variants addresses the theoretical cancer-promotion risk of TA-65 or cycloastragenol (DeBoy 2023).
  • Stop at rash or autoimmune flare: discontinuing at new rash, joint pain or flare of a known autoimmune condition limits hypersensitivity reactions and immune-driven worsening (NCCIH fact sheet).
  • Oral rather than injected forms: limiting use to oral root or extract avoids the rash and liver-test changes reported with intravenous astragalosides (Xu 2013).

Therapeutic Protocol

Timing, cycling, titration steps and other parameters without a citation reflect common practice.

  • Whole root (decoction or granules): 15 g raw-herb equivalent daily as granules for 48 weeks (Chan 2024); traditional Dang-gui buxue tang uses 30 g root with 6 g Angelica sinensis root (Examine astragalus page).
  • Root capsules or extract: 2.8 g root preparation three times daily (Liu 2016); 500 mg root extract twice daily (Banihashemi 2025); 480 mg standardized extract daily as two 240 mg capsules (Lippi 2025).
  • Isolated compounds: astragaloside IV 5–10 mg daily (Examine astragalus page); TA-65 16 mg daily (Bawamia 2023) or 250 units daily, the only significant dose in Salvador 2016.
  • Competing approaches: Traditional Chinese medicine uses astragalus inside multi-herb formulas matched to a symptom pattern; supplement users take single-herb extracts; longevity clinics promote TA-65, popularized by TA Sciences founder Noel Thomas Patton’s PattonProtocol-1 (Harley 2011).
  • Upper safety bound: up to 60 g root daily for 4 months does not seem to cause adverse effects, though no thorough safety evaluation exists (NCCIH fact sheet).
  • Time of day: No trial compared timing. Root trials split doses across the day; the TA-65 trial gave it in the morning on an empty stomach (Salvador 2016); traditional practice takes the tonic earlier in the day.
  • Half-life: astragaloside IV clears with a 2.1–2.7-hour half-life (Xu 2013); polysaccharides act locally in the gut, so blood half-life matters less for them.
  • Single versus split dosing: the short half-life favors splitting into 2–3 doses, matching the fatigue trials (Liu 2016; Banihashemi 2025); TA-65 is taken once daily.
  • Genetic polymorphisms: No variant guides dose. Known telomere-lengthening variants (POT1) argue against telomerase activators (DeBoy 2023).
  • Sex: No sex-specific dosing exists; women in the diastolic-function trial responded at 10 g but not 5 g daily (Li 2018).
  • Age: No trial set age-specific doses; the TA-65 trial in adults aged 53–87 gave 250 or 1,000 units daily regardless of age (Salvador 2016); lower starting doses are common practice in older adults on multiple drugs.
  • Baseline biomarkers: Baseline eGFR, HbA1c, blood pressure and lymphocyte count define what change is achievable; in a meta-analysis, the kidney benefit of astragalus injection related to baseline creatinine (Zhang 2019).
  • Pre-existing conditions: Kidney disease and diabetes trials used standard doses on top of usual drugs (Chan 2024); autoimmune disease and transplantation are exclusions, not dose adjustments.

Discontinuation & Cycling

  • Lifelong or short-term: Traditional use is long-term; trials lasted 2 weeks to 12 months (Chen 2012; Chan 2024; Salvador 2016), so safety beyond one year is unstudied.
  • Withdrawal effects: None have been reported in any trial or case report.
  • Tapering: Not needed for astragalus itself. For people on tacrolimus, drug levels may rise back after stopping, so levels are rechecked (Yang 2021).
  • Cycling: No study has tested cycling. Traditional practice pauses tonics during acute fever or infection; whether telomere gains persist after stopping TA-65 is unknown.

Sourcing and Quality

  • Correct species and plant part: Medicinal product is the dried root of Astragalus mongholicus (syn. Astragalus membranaceus); some other Astragalus species contain the nerve toxin swainsonine (a review, Stegelmeier 1999).
  • Formulations: Options include sliced root for decoction, granules, capsules of root powder, extracts standardized to astragaloside IV or polysaccharides, and purified cycloastragenol (TA-65); trial results apply only to the form tested.
  • Third-party testing: USP (United States Pharmacopeia) or NSF (an independent certification body) seals, or certificates of analysis covering identity, heavy metals, pesticide residues and microbial load, reduce contamination and misidentification risk; ConsumerLab has not tested astragalus products.
  • Brands: TA-65 is sold only by TA Sciences; the knee-pain trial used Axtragyl (Lippi 2025). Widely distributed single-herb root products include Nature’s Way and Gaia Herbs; none has published clinical data.

Practical Considerations

  • Time to effect: Fatigue changed within 4 weeks (Liu 2016), knee pain within 5 days (Lippi 2025), kidney function over 48 weeks (Chan 2024) and telomere length over 6–12 months (Salvador 2016).
  • Common pitfalls: Applying injection or multi-herb trial results to single-herb capsules; equating longer blood-cell telomeres with longer life; buying unidentified “milk vetch”; combining with immunosuppressants without telling the prescriber.
  • Regulatory status: In the U.S., astragalus is a dietary supplement not approved by the Food and Drug Administration for any condition (NCCIH fact sheet); TA-65’s seller agreed to a 2018 FTC consent order barring false or unsubstantiated health claims (Federal Register notice).
  • Cost: TA-65 has been priced at about $600 a bottle, while bulk astragalus root extract costs under $20 per pound (NutritionFacts video). Neither form is reimbursed by insurers or national health systems, so no payer incentive favors either.

Interaction with Foundational Habits

  • Sleep: Indirect, potentiating. No trial measured sleep as a primary outcome, but polysaccharide treatment reduced insomnia scores during chemotherapy (Shen 2024) and fatigue fell in two oral trials (Liu 2016; Banihashemi 2025). No insomnia signal has been reported; evening doses appear acceptable.
  • Nutrition: Indirect. Traditionally simmered into soups and congee (rice porridge) as a medicinal food; taking it with meals limits mild nausea. It depletes no known nutrients, and its glucose-lowering effect, pooled in a meta-analysis (Hong 2024), adds to low-glycemic eating patterns (foods that raise blood sugar slowly).
  • Exercise: None for strength, blunting for inflammation. During 10 weeks of resistance training, astragalus did not improve strength but kept TNF-α (tumor necrosis factor alpha) and IL-6 (interleukin 6), both inflammatory messengers, lower after a 2-week block of intensified training (Villanova 2026); elite rowers showed steadier immune cells (Latour 2021).
  • Stress management: Indirect. Astragalus is classed as an adaptogen (a substance theorized to raise stress resistance) (NCCIH fact sheet), but cortisol fell equally with astragalus and placebo during intensified training (Villanova 2026); no direct cortisol-lowering effect is shown.

Monitoring Protocol & Defining Success

Before starting, a baseline panel records kidney function, blood sugar, liver enzymes, blood counts and inflammation, plus home blood pressure, so that later changes can be attributed to astragalus and safety problems detected. For people on immunosuppressants, the panel also includes a baseline drug level. Telomere length is optional and useful only for those taking TA-65 or cycloastragenol, using the same laboratory and method each time.

Ongoing monitoring follows this cadence: home blood pressure and, for people on glucose-lowering drugs, fasting glucose during weeks 1–4; a repeat panel at 3 months; then every 6–12 months while use continues. Telomere length, if measured, is repeated no sooner than 12 months. Success means a meaningful change in the target measure (e.g., slower eGFR decline or lower HbA1c) or in fatigue, with no safety flags.

Biomarker Optimal Functional Range Why Measure It? Context/Notes
eGFR and serum creatinine Creatinine 0.6–1.3 mg/dL; eGFR above 60 mL/min/1.73 m² (standard reference range) Expected change: kidney benefit; safety check Morning blood draw; no heavy exercise or high meat intake 24 h before; compare eGFR slope with own baseline (Chan 2024)
HbA1c 4.0–5.6% (standard reference range) Expected change: lower glucose Reflects about 3 months; pair with fasting glucose; repeat no sooner than 3 months
Fasting glucose 70–99 mg/dL (standard reference range) Safety check: additive lowering on diabetes drugs 8–12 h fast; continuous glucose monitor readings useful in the first weeks
ALT and AST ALT 7–56 U/L; AST 10–40 U/L (standard reference range) Safety check: liver strain ALT (alanine aminotransferase) and AST (aspartate aminotransferase) are liver enzymes; no alcohol or strenuous exercise 48 h before testing
Absolute lymphocyte count 1.0–4.8 × 10⁹/L (standard reference range) Expected change: immune effect of TA-65 Part of a complete blood count; acute infection distorts results (Bawamia 2023)
hsCRP No established target; track change from own baseline Expected change: inflammation Repeat if above 10 mg/L, which signals acute illness; pair with lymphocyte count
Tacrolimus or cyclosporine trough level No established target; track the range set by the transplant team Safety check: level can fall Drawn just before the next dose (Yang 2021)
Leukocyte telomere length No established target; track change from own baseline Expected change: TA-65 effect Same lab and method each time; the TA-65 trial used Q-FISH (fluorescent-probe imaging of telomeres) at one laboratory and ran all timepoints together (Salvador 2016)

Qualitative markers:

  • Energy and fatigue, ideally scored with a simple 0–10 daily rating or the Brief Fatigue Inventory
  • Frequency and duration of colds and other infections
  • Joint pain during walking or stair climbing
  • Digestive comfort, skin rashes and any joint or autoimmune symptoms
  • Light-headedness on standing, as a sign of additive blood pressure lowering

Emerging Research

  • TA-65 and microvascular aging (NCT05598359): Medical College of Wisconsin, 180 participants, placebo-controlled, primary endpoint nitric-oxide-mediated skin blood-vessel dilation; not yet recruiting, completion 2029. A positive result would give TA-65 its first functional vascular benefit; a null result would leave telomere effects without functional support.
  • Astragalus in Alzheimer’s disease (NCT06694597): Phase 2, 76 participants, Clinical Dementia Rating primary endpoint; completed March 2024, no results posted. Positive results would move cognition from Speculative toward Medium; null results would weaken the neuroprotection rationale.
  • Astragalus dose comparison in Alzheimer’s disease (NCT05578443): Phase 2, 66 participants, 10 g versus 20 g daily, cognition at 48 weeks; registered completion July 2025 passed, status unknown, no results posted. A positive result would move cognition toward Medium and indicate a dose; a null result would weaken the neuroprotection case.
  • Astragalus during lymphoma chemotherapy (NCT06510530): Phase 3, 60 participants, double-blind, quality-of-life endpoint; not yet recruiting, completion 2032. A positive result would extend the fatigue item to lymphoma chemotherapy and to a trial outside China, Taiwan and Iran; a null result would support the null injected-polysaccharide finding (Shen 2024).
  • Astragalus with gemcitabine in pancreatic cancer (NCT06234072): Phase 2, 120 participants, double-blind, intravenous astragalus injection, objective response endpoint; listed as not yet recruiting with completion January 2027. Positive results would add single-herb injection evidence, indirect for oral supplements; null results would weaken extrapolation from multi-herb formulas.
  • Independent TA-65 replication: The only TA-65 meta-analysis flagged inflated effects in industry-funded trials and misreported its sources (Su 2025); the TA-65-plus-resveratrol arm of a 2-year trial was stopped early for a cholesterol rise attributed to resveratrol (Muscari 2026).
  • Long-term cancer safety: Long-telomere syndromes show that sustained telomere maintenance can raise cancer risk (DeBoy 2023); multi-year surveillance of telomerase-activator users could strengthen or weaken the longevity case.
  • Hard kidney outcomes: Chan’s trial measured eGFR slope, not dialysis or death (Chan 2024); larger outcome trials could confirm or overturn the kidney benefit.

Conclusion

Astragalus is a traditional Chinese root tonic whose compounds act on immune cells, inflammation and the enzyme that maintains the protective caps on chromosomes. Most of its human evidence comes from people who already have a disease. In type 2 diabetes, adding it to usual treatment lowered long-term blood sugar across many small trials from several research groups. Trials from two independent groups reduced fatigue. Single trials point to slower loss of kidney filtering capacity in diabetes-related kidney disease, modestly lower blood pressure, better recovery after bleeding in the brain and less knee pain, the last in a study paid for by the extract’s maker.

For its longevity claims, the evidence is weaker. The purified chromosome-cap product lengthened those caps in blood cells in studies largely produced by its seller, which a federal regulator sanctioned over its advertising, but no study has shown longer life, better physical function or fewer age-related diseases in people. Many of the most impressive results come from injections or multi-herb formulas rather than the oral root, and most trials are small, short and of low quality.

Side effects in trials were mild and no more common than with comparison treatments. The main concerns are interference with anti-rejection and other immune-suppressing drugs, possible worsening of autoimmune disease, and the unresolved question of cancer risk from long-term activation of the chromosome-cap enzyme. Astragalus is a low-risk root with modest benefits shown mainly in people with disease, not a proven way to slow aging.

Top - Benefits - Risks - Protocol